Search

Charmed-particle production in pp interactions at 70 GeV/c was studied with the SVD setup at the IHEP accelerator (Protvino). The experimental procedure used and the data-selection methods are described. Data obtained by using a quickly cycling bubble chamber and a magnetic spectrometer are analyzed. The number of inelastic-interaction events recorded in the chamber is 109000, with the charge multiplicity being n[sub ch] ≥ 4. The corresponding statistics are 4.96 event/µb. Part of the events were recorded in the magnetic spectrometer. Three three-prong decays of charged particles near the primary vertex are found on the films, two of these being recorded with the spectrometer. All three are interpreted as D[sup -] decays. Two neutral decays observed simultaneously in the chamber and in the spectrometer are interpreted as &Dmacr;[sup 0] decays. The total cross section for c&cmacr; production in the Feynman variable region -1 < x [sub F] < +1 is estimated at σ (c&cmacr;) = 1.6[sup +1.1][sub -0.7](stat.) ± 0.3 (syst.) µb. The cross-section values and the mean values 〈x[sub F]〉 and 〈p&perp〉 for D mesons are compared with other experimental results in the energy range 58-800 GeV. The data of this experiment are compatible with the cross-section estimates obtained in the beam-dump experiment at 70 GeV and with those predicted by perturbative QCD. [ABSTRACT FROM AUTHOR]

Epilepsy is one of the most studied chronic neurological disorders in the world. Despite significant progress in epilepsy research, some patients continue to experience recurrent seizures. It has been proven that oxidative stress plays an important role in epilepsy. Targeting oxidative stress may provide a novel therapeutic intervention to attenuate epileptogenesis as well as cognitive and psychiatric impairment in patients with epilepsy. One of the promising directions in the search for new strategies for the treatment of epilepsy is the combined use of antiepileptic drugs with antioxidants that affect the pathogenetic links of this disease. The new Russian antiepileptic drug fenosanoic acid (Dibufelon) has an anticonvulsant effect due to the inhibition of lipid peroxidation of brain cells and the reconstruction of cell membranes. This mechanism of action also paves the way for an increase in the effectiveness of co-administered drugs with phenosanoic acid. The effect of the drug on the cognitive and mental functions of patients, the regression of asthenia phenomena is also observed. The clinical efficacy and safety of the combination of this drug with other antiepileptic drugs in epilepsy has been demonstrated in experimental and clinical studies.